On Friday, Mizuho maintained a Neutral rating on shares of Neurocrine (NASDAQ:NBIX) Biosciences with a price target of $140.00. The firm acknowledged the recent FDA approval of Bristol Myers (NYSE:BMY) Squibb's schizophrenia drug, Cobenfy, noting its potential to change the treatment landscape due to its efficacy and safety profile compared to current atypical antipsychotics.
Cobenfy is notable for not carrying a Black Box warning, which is common among antipsychotics and was a major concern prior to the FDA's decision.
The approval of Cobenfy, the first muscarinic agonist for schizophrenia, is expected to significantly affect the market. Mizuho pointed out the surprise inclusion of several warnings and precautions on Cobenfy's label that were not observed in clinical studies. These warnings seem to stem from the drug's trospium component, suggesting that other muscarinic agents in development without trospium may have the advantage of a cleaner label.
Despite the transformative potential of Cobenfy, Mizuho expressed that the drug's label contains more warnings and precautions than anticipated. These cautionary notes did not appear in the clinical studies for schizophrenia but are likely related to the trospium content in Cobenfy. This insight suggests that upcoming muscarinic agonists, such as ABBV's emraclidine and Neurocrine's NBI-568, which are single-molecule drugs without trospium, could have an edge with fewer label warnings.
Even with these considerations, Cobenfy enjoys a significant first-mover advantage in the market. It is expected to be years ahead of other muscarinic drugs in development. This head start could be crucial for Bristol Myers Squibb as it establishes Cobenfy in the treatment regimen for schizophrenia before competitors arrive.
Mizuho's commentary underscores the competitive dynamics in the development of new treatments for schizophrenia, highlighting the balance between drug efficacy, safety, and regulatory labeling that can influence a drug's success in the market. Neurocrine Biosciences, with its own muscarinic agent NBI-568 in development, remains a company to watch as the landscape evolves.
In other recent news, Neurocrine Biosciences has decided to halt the development of its drug luvadaxistat, which was being studied for cognitive impairment associated with schizophrenia (CIAS). The decision followed inconsistent results in the ERUDITE Phase 2 clinical study.
Analysts from BMO Capital Markets maintained their Market Perform rating for Neurocrine despite this development, as they anticipate only minor pressure on the company's stock due to CIAS not being a major focus for investors. Neurocrine is now focusing on advancing its other drugs, '568 for schizophrenia and '845 for major depressive disorder (MDD).
In the wake of these developments, several analyst firms have weighed in on Neurocrine's prospects. Piper Sandler upgraded the company's stock from Neutral to Overweight, citing confidence in the company's investigational drug NBI-1117568, also known as NBI-'568. However, BMO Capital Markets reduced its price target due to uncertainties in trial results, yet maintained a Market Perform rating.
On the other hand, H.C. Wainwright reaffirmed its Buy rating for Neurocrine following a dose-finding study for NBI-1117568, which indicated a statistically significant improvement.
Neurocrine Biosciences has also reported over 30% year-over-year growth in sales of their drug, INGREZZA, leading to an increase in their sales guidance for the year to a range of $2.25 billion to $2.3 billion. The company is also awaiting FDA approval for Crinecerfont, a drug for congenital adrenal hyperplasia, which would further expand its product portfolio.
InvestingPro Insights
As Neurocrine Biosciences remains in focus following Mizuho's neutral stance, InvestingPro data and tips offer an additional dimension to the company's financial health and market performance. Neurocrine Biosciences is currently trading at a P/E ratio of 33.94, which is expected to adjust to 24.47 in the coming months, suggesting a more attractive valuation in relation to its near-term earnings growth. Additionally, the company's revenue has shown a robust growth of 26.69% over the last twelve months as of Q2 2024, with a quarterly increase of 30.37% in Q2 2024, indicating a strong upward trajectory in financial performance.
InvestingPro Tips highlight that analysts are optimistic about Neurocrine's prospects, with 10 analysts having revised their earnings upwards for the upcoming period. This consensus could reflect confidence in the company's pipeline and market strategy. Moreover, the company's stock is considered to be in oversold territory according to the Relative Strength Index (RSI), which might signal a potential buying opportunity for investors considering the company's growth prospects and the competitive landscape of schizophrenia treatments.
For readers seeking a deeper analysis, there are additional InvestingPro Tips available on the platform, which can provide more nuanced investment guidance. Neurocrine Biosciences, with its promising NBI-568 in development, is poised to be a key player in the evolving schizophrenia treatment market, and the InvestingPro platform offers further insights and metrics that could be valuable for investors monitoring the company's progress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.